News
A new project on Rituximab to Treat Primary Membranous Nephropathy is now available for feedback from all interested stakeholders.
Rituximab to Treat Primary Membranous Nephropathy
Call for Feedback: 2020-02-13
Feedback Due By: 2020-02-28
Consultation Document: Proposed Project Scope
Product Type: Health Technology Assessment
Submit Feedback
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.
Today, CADTH has issued final recommendations for:
upadacitinib (Rinvoq)
Indications: Arthritis, Rheumatoid
Recommendation: Reimburse with clinical criteria and/or conditions
For more information
See Pharmaceutical Reviews Update – Issue 13 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include:
New consolidated document for pCODR procedures and guidelines
Clarifications regarding economic submission requirements
Update for patients and communities
Today, CADTH has issued final recommendations for:
Lorlatinib (Lorbrena) NSCLC
Funding Request: For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on: crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or...
